Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
- Authors
- Chen, Li-Shiun; Bloom, A Joseph; Baker, Timothy B; Smith, Stevens S; Piper, Megan E; Martinez, Maribel; Saccone, Nancy; Hatsukami, Dorothy; Goate, Alison; Bierut, Laura
- Year
- 2014
- Journal
- Addiction (Abingdon, England)
- PMID
- 24033696
- DOI
- 10.1111/add.12353
- PMCID
- PMC3946972
BACKGROUND AND AIMS: Evidence suggests that both the nicotinic receptor Ξ±5 subunit (CHRNA5) and Cytochrome P450 2A6 (CYP2A6) genotypes influence smoking cessation success and response to pharmacotherapy. We examine the effect of CYP2A6 genotype on smoking cessation success and response to cessation pharmacotherapy, and combine these effects with those of CHRNA5 genotypes. DESIGN: Placebo-controlled randomized smoking cessation trial. SETTING: Ambulatory care facility in Wisconsin, USA. PARTICIPANTS: Smokers (nβ=β709) of European ancestry were randomized to placebo, bupropion, nicotine replacement therapy or combined bupropion and nicotine replacement therapy. MEASUREMENTS: Survival analysis was used to model time to relapse using nicotine metabolism derived from CYP2A6 genotype-based estimates. Slow metabolism is defined as the lowest quartile of estimated metabolic function. FINDINGS: CYP2A6-defined nicotine metabolic function moderated the effect of smoking cessation pharmacotherapy on smoking relapse over 90 days [hazard ratio (HR)β=β2.81, 95% confidence interval (CI)β=β1.32-5.99, Pβ=β0.0075], with pharmacotherapy significantly slowing relapse in fast (HRβ=β0.39, 95% CIβ=β0.28-0.55, Pβ=β1.97βΓβ10(-8)), but not slow metabolizers (HRβ=β1.09, 95% CIβ=β0.55-2.17, Pβ=β0.80). Further, only the effect of nicotine replacement, and not bupropion, varies with CYP2A6-defined metabolic function. The effect of nicotine replacement on continuous abstinence is moderated by the combined genetic risks from CYP2A6 and CHRNA5 (Waldβ=β7.44, d.f.β=β1, Pβ=β0.0064). CONCLUSIONS: Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. The variation in treatment responses among smokers with genes may guide future personalized smoking cessation interventions.
Pharmacotherapy reduces relapse in fast nicotine metabolizers, but not in slow metabolizers defined by CYP2A6 genotype aa Time to relapse over 90 daysThere is a significant interaction between medication and CYP2A6 (interaction effect size=2.81, 95%CI=1.32-5.99, p=0.0075)
Effect of nicotine replacement therapy (NRT) on smoking relapse differs in fast vs. slow nicotine metabolizers defined by CYP2A6 genotype aThere is a significant interaction between NRT and CYP2A6 (interaction effect size=1.82, 95%CI=1.07-3.10, p=0.028).NRT: Nicotine Replacement Therapya Time to relapse over 90 days. b The group with NRT includes all treatment arms with NRT (the NRT arms and the arm receiving both NRT and bupropion. c The group without NRT includes all treatment arms without NRT (the placebo arm and the arm receiving bupropion alone).
Trajectory of post-quit smoking quantity varies by treatment and CYP2A6: Fast metabolizers on placebo treatment have a significantly faster escalation into heavy smoking over time (nicotine replacement therapy (NRT) vs. placebo)(3A) A significant interaction between active medication and CYP2A6 on the smoking rate escalation (t=3.13, df=1, p=0.0020).(3B) A trend interaction between NRT combination and CYP2A6 on smoking quantity over time (F=3.75, df =1; p=0.053)
Nicotine replacement therapy (NRT) vs. placebo effect on smoking abstinencea varies with the combined genetic effects of CYP2A6 and CHRNA5There is a significant interaction between pharmacotherapy (NRT vs. Placebo) and 4 genetic groups (wald=7.44, df=1, p=0.0064). Blue vertical lines are 95% confidence intervals.a Continued Abstinence for 3 months. b Low vs. risk for CYP2A6 indicates risk for smoking relapse defined by slow vs. fast metabolism. c Low vs. risk for CHRNA5 indicates risk for smoking relapse defined by CHRNA5 (rs16969968, rs680244) (low-risk diplotypes: GG_CC, GG_CT, GA_CC and high-risk diplotypes: GG_TT, GA_CT, AA_ CC).
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| The clinical usefulness of knowing <i>CHRNA5</i> polymorphism genotype: paving the way for personalized therapy. | Colombo F et al. | β | 2026 | β |
| Effect of very low nicotine content cigarettes on smoking behavior in Chinese smokers with genotype-stratified nicotine metabolism rates. | Ma W et al. | β | 2025 | β |
| Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community. | Wichman ML et al. | β | 2025 | β |
| Changes in distinct brain systems identified with fMRI during smoking cessation treatment with varenicline: a review. | Panagopoulos VN et al. | β | 2024 | β |
| Nicotine Abuse and Neurodegeneration: Novel Pharmacogenetic Targets to Aid Quitting and Reduce the Risk of Dementia. | Almahasneh F et al. | β | 2024 | β |
| Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6. | Tzoupis H et al. | β | 2024 | β |
| Tobacco use disorder in patients with other mental disorders: a dual disorder perspective from clinical neuroscience. | Szerman N et al. | β | 2024 | β |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | β | 2023 | β |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | β | 2023 | β |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Theodoulou A et al. | β | 2023 | β |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | β | 2023 | β |
| New medications development for smoking cessation. | Lengel D et al. | β | 2023 | β |
| Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. | Jones SK et al. | β | 2022 | β |
| The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials. | Bray M et al. | β | 2022 | β |
| TOBACCO USE DISORDER AND DUAL DISORDERS Joint statement by the Spanish Psychiatry Society and the Spanish Dual Disorders Society. | NΓ©stor S et al. | β | 2022 | β |
| Gene-based association analysis reveals involvement of LAMA5 and cell adhesion pathways in nicotine dependence in African- and European-American samples. | Fan R et al. | β | 2021 | β |
| Antidepressants for smoking cessation. | Howes S et al. | β | 2020 | β |
| Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. | Bray MJ et al. | β | 2020 | β |
| [Physiological and Psychological Data influencing Pregnant Women Smoking BehaviorΒ -Β CNGOF-SFT Expert Report and Guidelines for Smoking Management during Pregnancy]. | Berveiller P et al. | β | 2020 | β |
| Connectivity between visual and auditory cortices mediates the influence of argument strength on the effectiveness of smoking-cessation videos among smokers low in sensation seeking. | Shi Z et al. | β | 2019 | β |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Lindson N et al. | β | 2019 | β |
| Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. | Shahab L et al. | β | 2019 | β |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | β | 2019 | β |
| Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation. | Tran AX et al. | β | 2019 | β |
| Biosignature Discovery for Substance Use Disorders Using Statistical Learning. | Baurley JW et al. | β | 2018 | β |
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | Olfson E et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | β | 2018 | β |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| Smoking cessation in pregnancy: a continuing challenge in the United States. | Scherman A et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Toward precision medicine in addiction treatment. | Volkow N | β | 2018 | β |
| Use of hormonal contraceptives and smoking cessation: A preliminary report. | Allen AM et al. | β | 2018 | β |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | β | 2018 | β |
| A Novel Tobacco Use Phenotype Suggests the 15q25 and 19q13 Loci May be Differentially Associated With Cigarettes per Day and Tobacco-Related Problems. | Richmond-Rakerd LS et al. | β | 2017 | β |
| Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation? | Jao NC et al. | β | 2017 | β |
| Effectiveness of Switching Smoking-Cessation Medications Following Relapse. | Heckman BW et al. | β | 2017 | β |
| Lessons Learned From Past Gene-Environment Interaction Successes. | Ritz BR et al. | β | 2017 | β |
| Nicotine Metabolite Ratio (NMR) Prospectively Predicts Smoking Relapse: Longitudinal Findings From ITC Surveys in Five Countries. | Fix BV et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | Tanner JA et al. | β | 2017 | β |
| Significant association of the CHRNB3-CHRNA6 gene cluster with nicotine dependence in the Chinese Han population. | Wen L et al. | β | 2017 | β |
| Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women. | Baraona LK et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions. | Yang J et al. | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. | Fagan P et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| To quit or not: Vulnerability of women to smoking tobacco. | Park SJ et al. | β | 2016 | β |
| A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. | Loukola A et al. | β | 2015 | β |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | β | 2015 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. | Strong DR et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| Gender Considerations in Addiction: Implications for Treatment. | Polak K et al. | β | 2015 | β |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | β | 2015 | β |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | β | 2015 | β |
| Nicotine withdrawal. | McLaughlin I et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | β | 2015 | β |
| Commentary on Chen etβal. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? | David SP | β | 2014 | β |
| Genetics and smoking. | Loukola A et al. | β | 2014 | β |
| Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders. | Rutter JL et al. | β | 2014 | β |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | β | 2014 | β |
| The promise of using personalized genomic information to promote behavior change: is the debate over, or just beginning? | Graves KD et al. | β | 2014 | β |